Cited by 1,076Opioid Use Disorder TreatmentSubstance Abuse Treatment and OutcomesHIV, Drug Use, Sexual Risk

The DOI matches its Crossref record; 34 of the 38 references it cites were found in a registry or an index.

Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study

Open access

Larochelle, Marc R., Bernson, Dana, Land, Thomas, Stopka, Thomas J., Wang, Na, Xuan, Ziming, Bagley, Sarah M., Liebschutz, Jane M., Walley, Alexander Y.·2018·Annals of Internal Medicine

DOI 10.7326/m17-3107PMC PMC6387681

Open this paper in CoChat — free account

Abstract

Background: Opioid overdose survivors have an increased risk for death. Whether use of medications for opioid use disorder (MOUD) after overdose is associated with mortality is not known. Objective: To identify MOUD use after opioid overdose and its association with all-cause and opioid-related mortality. Design: Retrospective cohort study. Setting: 7 individually linked data sets from Massachusetts government agencies. Participants: 17 568 Massachusetts adults without cancer who survived an opioid overdose between 2012 and 2014. Measurements: Three types of MOUD were examined: methadone maintenance treatment (MMT), buprenorphine, and naltrexone. Exposure to MOUD was identified at monthly intervals, and persons were considered exposed through the month after last receipt. A multivariable Cox proportional hazards model was used to examine MOUD as a monthly time-varying exposure variable to predict time to all-cause and opioid-related mortality. Results: In the 12 months after a nonfatal overdose, 2040 persons (11%) enrolled in MMT for a median of 5 months (interquartile range, 2 to 9 months), 3022 persons (17%) received buprenorphine for a median of 4 months (interquartile range, 2 to 8 months), and 1099 persons (6%) received naltrexone for a median of 1 month (interquartile range, 1 to 2 months). Among the entire cohort, all-cause mortality was 4.7 deaths (95% CI, 4.4 to 5.0 deaths) per 100 person-years and opioid-related mortality was 2.1 deaths (CI, 1.9 to 2.4 deaths) per 100 person-years. Compared with no MOUD, MMT was associated with decreased all-cause mortality (adjusted hazard ratio [AHR], 0.47 [CI, 0.32 to 0.71]) and opioid-related mortality (AHR, 0.41 [CI, 0.24 to 0.70]). Buprenorphine was associated with decreased all-cause mortality (AHR, 0.63 [CI, 0.46 to 0.87]) and opioid-related mortality (AHR, 0.62 [CI, 0.41 to 0.92]). No associations between naltrexone and all-cause mortality (AHR, 1.44 [CI, 0.84 to 2.46]) or opioid-related mortality (AHR, 1.42 [CI, 0.73 to 2.79]) were identified. Limitation: Few events among naltrexone recipients preclude confident conclusions. Conclusion: A minority of opioid overdose survivors received MOUD. Buprenorphine and MMT were associated with reduced all-cause and opioid-related mortality. Primary Funding Source: National Center for Advancing Translational Sciences of the National Institutes of Health.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.7326/m17-3107

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Sensitivity analysis in observational research: Introducing the E-value
VanderWeele, T. J., & Ding, P. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2607 · Cited by 6,350
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Breen, C. L., Kimber, J., & Davoli, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub4 · Cited by 2,312
Increases in drug and opioid-involved overdose deaths – United States, 2010-2015
Rudd, R. A., Seth, P., David, F., & Scholl, L. (2016) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm655051e1 · Cited by 2,194
Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.
Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017) · BMJ · doi:10.1136/bmj.j1550 · Cited by 1,816
Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002209.pub2 · Cited by 1,654
Medication-Assisted Therapies — Tackling the Opioid-Overdose Epidemic
Volkow, N. D., Frieden, T. R., Hyde, P. S., & Cha, S. S. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1402780 · Cited by 1,014
Emergency Department–Initiated Buprenorphine/Naloxone Treatment for Opioid Dependence
D’Onofrio, G., O’Connor, P. G., Pantalon, M. V., Chawarski, M. C., Busch, S. H., Owens, P. H., Bernstein, S. L., & Fiellin, D. A. (2015) · JAMA · doi:10.1001/jama.2015.3474 · Cited by 913
Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial
Lee, J. D., Nunes, E. V., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., Farkas, S., Fishman, M., Gauthier, P., Hodgkins, C. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32812-x · Cited by 700
Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial
Krupitsky, E., Nunes, E. V., Ling, W., Illeperuma, A., Gastfriend, D. R., & Silverman, B. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60358-9 · Cited by 555
Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence
Mattick, R. P., Breen, C. L., Kimber, J., Davoli, M., & Breen, R. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002209 · Cited by 536

Flagged first, then by citations

Show all 38 references

4 of the 38 references couldn’t be matched to a known paper.

Sorted by citations

Items 801–900 of 1,000

Establishing Buprenorphine for Acute Postoperative Pain Management
Abelleira, A., & Hickey, T. R. (2025) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/15360288.2025.2524688 · Cited by 2
Oral Health Risks of Transmucosal Buprenorphine: Commentary on Tuan et al. and Zheng et al.
Black, A. C., & Becker, W. C. (2025) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001452 · Cited by 1
Patient-Centered Outcomes Associated With a Novel Office-Based Opioid Treatment Program in a District Health Department: Mixed Methods Pilot Study
Coles, T., Chen, H., Marais, A. C. D., Sachdeva, N., Bush, C. A., Harrison, L. M., & Guthrie, S. (2023) · JMIR Formative Research · doi:10.2196/40897 · Cited by 1
Access to Medications for Opioid Use Disorder During COVID-19: Retrospective Study of Commercially Insured Patients from 2019–2022
Rajagopal, S., Westra, J. R., Raji, M. A., Wilkes, D. M., & Kuo, Y. (2023) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2023.11.011 · Cited by 1
The Intersection of Substance Use Disorders and Infectious Diseases in the Emergency Department
Anderson, E. S., & Frazee, B. W. (2024) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2024.02.004 · Cited by 1
A theoretical explanation of naloxone provision among primary care physicians and community pharmacists in Tennessee
Salwan, A., Mathis, S. M., Brooks, B., Hagemeier, N. E., Tudiver, F. G., Foster, K. N., Alamian, A., & Pack, R. P. (2024) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2024.07.001 · Cited by 1
Buprenorphine/naloxone initiation in the emergency department: A series of vignettes
Popova, M., Chung, K., Raman, S., Batra, S., Nakitende, D., & Boniface, K. S. (2024) · JEM Reports · doi:10.1016/j.jemrpt.2024.100112 · Cited by 1
Exploring the Lived Experiences of Medication for Opioid use Disorder Treatment: A Qualitative Study among a Crowdsourced Convenience Sample
Victor, G. A., Kheibari, A., & Strickland, J. C. (2024) · Community Mental Health Journal · doi:10.1007/s10597-024-01345-9 · Cited by 1
Attitudinal barriers to buprenorphine prescription and former waiver training
Gannon, M. P., Tello, M. A., Wakeman, S. E., Charles, J.-P., Lipsitz, S. R., & Samal, L. (2024) · Journal of Opioid Management · doi:10.5055/jom.0827 · Cited by 1
Associations Between State Policies Facilitating Telehealth and Buprenorphine Episode Initiation and Duration Early in the COVID Pandemic
Stein, B. D., Saloner, B. K., Sheng, F., Sorbero, M., Dick, A. W., & Gordon, A. J. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-024-09188-6 · Cited by 1
Redefining low-threshold buprenorphine access in an integrated mobile clinic program: Factors associated with treatment retention
Harris, R., Stracker, N. H., Rice, M., Clair, A. S., Page, K. R., & Rosecrans, A. M. (2024) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209586 · Cited by 1
State Medicaid Policies Governing Access to Medications for Opioid Use Disorder (MOUD) and MOUD Treatment Use in a Large Sample of People Who Inject Drugs in 20 U.S. States
Yarbrough, C. R., Cooper, H. L. F., Beane, S., Haardörfer, R., Ibragimov, U., Haley, D. F., Linton, S., Landes, S., Lewis, R., Sionéan, C., et al. (2024) · Substance Use & Misuse · doi:10.1080/10826084.2024.2440365 · Cited by 1
Patient acceptance of emergency department-initiated buprenorphine and reasons for declining
Jennings, L. K., Smith, A. B., Moreland, A. D., Ward, R. C., Gainey, S. S., Lane, S. M., Holodnik, O., Scarpino, K., Hartwell, K. J., Haynes, L. F., et al. (2025) · JEM Reports · doi:10.1016/j.jemrpt.2025.100141 · Cited by 1
Statewide implementation for medications for opioid use disorder (MOUD) in urban and rural emergency departments
Greenwood‐Ericksen, M. B., Blasi, M., Warrick, B. J., Cotton, J., Ketcham, E. M., Ketcham, C., Wait, S., Abeyta, R., Ziedonis, D. M., & Salvador, J. G. (2025) · The Journal of Rural Health · doi:10.1111/jrh.70011 · Cited by 1
Civil Rights Laws for People With Opioid Use Disorder in the Emergency Department
South, A.-M., Hawk, K. F., Friedman, S., Lofwall, M. R., Fanucchi, L. C., & Cohen, S. M. (2025) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001480 · Cited by 1
Risk of self-harm and overdose after starting buprenorphine for opioid use disorder
Simon, G. E., Shortreed, S. M., Johnson, E., Ahmedani, B. K., Sterling, S., Campbell, C. I., Hechter, R. C., Ziebell, R. A., & Parthasarathy, S. (2025) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2025.06.010 · Cited by 1
The Largest Program for Opioid Use Disorder in a Statewide Carceral System: A Collaborative Multi‐Agency Initiative
Jordan, A. E., GAYNOR, R., MOORES, C., CANTY, Y., & Cunningham, C. O. (2025) · Milbank Quarterly · doi:10.1111/1468-0009.70048 · Cited by 1
Medicaid Unwinding: Association With New and Ending Buprenorphine Treatment Episodes
Landis, R. K., Sheng, F., & Stein, B. D. (2025) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001573 · Cited by 1
Treatment and Referral of Youth With Opioid Addiction in the Pediatric Emergency Department: A Pilot Study
Devlin, G., Bernabe, N., Lim, I., & Nager, A. L. (2025) · Academic Pediatrics · doi:10.1016/j.acap.2025.103143 · Cited by 1
Outcomes of a Hospitalist-Led Consult Service for Patients with Opioid Use Disorder: A Propensity Score Weighted Study
Clifton, D., Ivey, N., Platt, A. C., Hong, C., & Setji, N. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09820-z · Cited by 1
Hospital Care for Pregnant Persons With OUD Review
Park, J., Terplan, M., & Ratner, J. (2025) · American Journal of Medicine Open · doi:10.1016/j.ajmo.2025.100117 · Cited by 1
Impacts of Disruptive Events on Addictive Behavioral Patterns: A Cross‐Sectional Study of Methadone Maintenance Therapy During the COVID‐19 Pandemic in Iran
Toreyhi, Z., Rezai-Mersagh, A. M., Kheradmand, A., & Mehrvar, R. (2025) · Health Science Reports · doi:10.1002/hsr2.71580 · Cited by 1
A descriptive study of drug overdose epidemics, overdose prevention efforts, and opioid settlement fund distribution across six states
Li, Z., Chiddawar, T. V., Shaw, L. C., Dennis, A., Lieberman, A. J., Kingsepp, A., Trinidad, A. J., Tuazon, E. D., Welch, A. E., Chatterjee, A., et al. (2025) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2025.105100 · Cited by 1
Self-citation
Practical guidance for navigating buprenorphine discontinuation
Sonoda, K., Hilmer, A., & Bello, J. K. (2025) · Harm Reduction Journal · doi:10.1186/s12954-025-01353-2 · Cited by 1
Implementation facilitation improves readiness for emergency department-initiated buprenorphine to treat opioid use disorder
Strout, T. D., Dziura, J. D., Barrett, T. W., Cowan, E. A., Hawk, K. F., Herring, A. A., Manteuffel, J. J., Martel, S. H., Owens, P. H., McCormack, R. P., et al. (2025) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2025.209845 · Cited by 1
Target product profile: An essential tool to deliver differentiated, patient-centered, and reimbursable medical products to treat substance use disorders
Nguyen, T., & Koustova, E. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104573 · Cited by 1
Morbidity, mortality, and health outcomes following emergency department visits for fentanyl-related overdoses: A retrospective cohort study
Choo, L. Y., Nash, S., Farmer, B., Mallow, Z., Miller, L. E., Six-Workman, E. A., Mahoney, J. J., & Winstanley, E. L. (2025) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2025.100405 · Cited by 1
Emergency Department Presentations Related to the Abuse of Illicit and Prescription Opioids Through a European Sentinel-centres–Based Registry
Lyphout, C., Paepe, P. D., Dines, A. M., Fc, E., Giraudon, I., Heyerdahl, F., Hovda, K. E., Liechti, M. E., Miró, Ò., Vallersnes, O. M., et al. (2025) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001632 · Cited by 1
Acceptability of and Implementation Supports for Video Directly Observed Treatment to Enhance Methadone Dosing Flexibility in a Multisite Opioid Treatment Program: Qualitative Rapid Needs Assessment Study
Tsui, J. I., Austin, E. J., Dunn, J. A., Gojic, A. J., Bhatraju, E. P., Darnton, J. B., Grekin, P., Soth, S., Woolworth, S., Williams, E. C., et al. (2026) · JMIR Formative Research · doi:10.2196/84162 · Cited by 1
Impact of Medication for Opioid Use Disorder on Patient Directed Discharge Among Patients with Opioid Use Disorder
Singh‐Tan, S., Jakubowski, A. U., Huxley‐Reicher, Z., Torres‐Lockhart, K., Ceresnak, J., Pacífico, J., Arnsten, J. H., & Southern, W. N. (2026) · Journal of General Internal Medicine · doi:10.1007/s11606-026-10172-5 · Cited by 1
Tailoring of a chronic pain self-management intervention for individuals with opioid use disorder in office-based addiction treatment
Hamm, M., Emerson, R., Rogal, S. S., Bulls, H. W., Nugent, S. M., Anderson, A. J., Nash, S., Salay, M., Winstanley, E. L., Cameron, F. D. A., et al. (2026) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2026.209910 · Cited by 1
Navigating Substance Use Care in the Emergency Department: A Scoping Review
Naeem, A. H., Kapadia, J., Soske, J., Zhang, R., Kirchwey, T., Fan, M., Becker, S. J., Merrick, C., Goodman, G. R., & Samuels, E. A. (2026) · Journal of the American College of Emergency Physicians Open · doi:10.1016/j.acepjo.2025.100318 · Cited by 1
Overcoming Legislative and Institutional Barriers to Implementing Methadone Dispensing in a California Health System
Cummins, S., Lopez, J., Dakwa, D. S., Nguyen, D., Weng, R., Eberhardt, C. S., & Moulin, A. K. (2026) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70187 · Cited by 1
Algorithmic opacity in opioid risk scoring and the need for transparent AI regulation
Sherry Yun, W. A. N. G., Stofer, R., Yu, Q., Li, A., Mai, G., & Wang, H. (2026) · npj Digital Medicine · doi:10.1038/s41746-026-02491-y · Cited by 1
Buprenorphine utilization following removal of prior authorization requirements in the Kentucky Medicaid population
Miracle, D. K., Hammerslag, L. R., Slavova, S. S., Lofwall, M. R., WALSH, S. L., Talbert, J., & Freeman, P. R. (2026) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2026.113105 · Cited by 1
Rapid Buprenorphine Initiations for Cardiac Emergencies in Patients on High-dose Methadone: A Case Report
Fourie, E., Mitchell, M. T., Anaya, P., Fanucchi, L. C., & South, A.-M. (2025) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001615 · Cited by 1
Longitudinal Patterns of Dental Health Care Utilization 18 Months Before and 36 Months After Initiation of Index Medications for Opioid Use Disorder
Roy, P. J., Yuan, N., Li, Y., Butler, A. M., Nickel, K. B., Gibson, G., Hubbard, C. C., Boyer, T. L., Suda, K. J., & Durkin, M. J. (2026) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001675 · Cited by 1
Burden of overdoses among persons with opioid use disorder in the United States, 2025–2028: a simulation modeling study
Nataraj, N., Chen, Y., Stewart, A., Rikard, S. M., Zhang, K., Rice, K., Jiang, X., Mattson, C. L., Ko, J. Y., Guy, G. P., et al. (2026) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2026.101435 · Cited by 1
A Digital Therapeutic Mobile App, ReSET-O, as Adjunct to Medication Treatment for Opioid Use Disorder: A Randomized Clinical Trial at an Opioid Treatment Program
Kawasaki, S. S., Lehman, E. B., Kong, L., Spangler, A., Aydingolo, N., & Nunes, E. V. (2026) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001682 · Cited by 1
Treatment gaps for opioid use disorder among commercially insured US surgical patients, 2016–2022
Ervin-Sikhondze, B. A., Nguyen, T. D., Lagisetty, P., Hu, H. M., Waljee, J. F., Brummett, C. M., Li, Y., & Bicket, M. C. (2026) · Regional Anesthesia & Pain Medicine · doi:10.1136/rapm-2026-107625 · Cited by 1
Advancing Opioid Use Disorder Treatment: A Narrative Review of Evidence-Based Solutions to Systems-Level Barriers in the US
Bailey, A., Kang, A. W. C., & Martin, R. A. (2026) · Substance Use & Addiction Journal · doi:10.1177/29767342261452648 · Cited by 1
A Virtual Reality Intervention to Promote Uptake of Medications for Opioid Use Disorder in the Emergency Department Following Opioid-Involved Overdose Based on Input From People With Lived Experience: Development Study
Trost, Z., Won, A. S., Boyapati, H. P. N., Costa, K., Davenport, J., D’Onofrio, G., Drager, L. R., Shum, P. C., Pierce, M. W., Fraenkel, L., et al. (2026) · JMIR XR and spatial computing. · doi:10.2196/84397 · Cited by 1
Buprenorphine and acute pain in the fentanyl era: a graded competition model
Albert, O. M. (2026) · British Journal of Anaesthesia · doi:10.1016/j.bja.2026.06.040 · Cited by 1
Adverse events reported to FDA Adverse Event Reporting System for long-acting injectable buprenorphine during the first 18 months postlaunch
Dawson, B. J., Frost, M. P., Budilovsky-Kelley, N. R., Fiore, G. J., Friedman, A., Kaempfer, C., & Cohen, J. M. (2026) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2026.210095 · Cited by 1
Methadone vs Buprenorphine-Naloxone in Opioid Overdose Survivors
Kleinman, R. A., Larney, S., Sule, N. O., Ma, C., Hauck, T. S., & Kurdyak, P. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.29313 · Cited by 1
Opiate Use in the Military Context
Colston, M. (2019) · Springer eBooks · doi:10.1007/978-3-030-05384-0_11 · Cited by 1
Substance Use: A Social Emergency Medicine Perspective
Samuels, E. A., Xuan, Z., & Bernstein, E. (2021) · Springer eBooks · doi:10.1007/978-3-030-65672-0_10 · Cited by 1
Self-citation
Transforming Opioid Addictions Care in New Mexico: Combining Medication Treatment with Patient Autonomy, Civic Engagement and Integrative Healing
Taneja, A., & Wagner, W. (2021) · Leading Community Based Changes in the Culture of Health in the US - Experiences in Developing the Team and Impacting the Community · doi:10.5772/intechopen.98463
The insanity of addiction treatment in America
Proctor, S. L., Lipsey, J., & Rigg, K. K. (2021) · Addiction Research & Theory · doi:10.1080/16066359.2021.2007888 · Cited by 1
Being Part of the Solution
Denno, J., Burns, S., Rucker-Christopher, Z., & Suriano, D. (2022) · Advanced Emergency Nursing Journal · doi:10.1097/tme.0000000000000407 · Cited by 1
Factors associated with counselling adherence in opioid treatment programs
Placide, V., Unruh, L. Y., Atkins, D. N., Chisholm, L., & Scott, J. B. (2022) · Health & Social Care in the Community · doi:10.1111/hsc.14069 · Cited by 1
A qualitative study: harm reduction and opioid overdose strategies for Black and Latinx opioid overdose survivors
Serrano, M. D. (2022) · Journal of Social Work Practice in the Addictions · doi:10.1080/1533256x.2022.2149970 · Cited by 1
Changing approaches to treating opioid withdrawal in the USA
Hughes, M. E., Edinoff, A. N., & Sue, K. L. (2023) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00145-1 · Cited by 1
Emergency Department Buprenorphine Quality Improvement and Emergency Physician Knowledge, Attitudes, and Self-Efficacy
Myles, M. L., Scott, K., Ziobrowski, H. N., Helseth, S. A., Becker, S. J., & Samuels, E. A. (2023) · Western Journal of Emergency Medicine · doi:10.5811/westjem.59477 · Cited by 1
Preparing Medical Students to Care for Patients with Opioid Use Disorder: Buprenorphine Waiver Training in Undergraduate Medical Education
Riser, E., Kennedy, A. G., Holterman, L. A., Brooklyn, J. R., Maruti, S., & Sobel, H. G. (2024) · Academic Psychiatry · doi:10.1007/s40596-024-01968-w · Cited by 1
Impact of the COVID-19 Pandemic on Functions of Nursing Professionals in the Care of Opioid Use Disorder
Brown, K. G., Chen, C. Y., Dong, D., Lake, K. J., & Butelman, E. R. (2024) · Journal of Addictions Nursing · doi:10.1097/jan.0000000000000573 · Cited by 1
Considerations when prescribing opioid agonist therapies for people living with HIV
Tarfa, A., Lier, A., Shenoi, S., & Springer, S. A. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2375448 · Cited by 1
Initiation of Buprenorphine in the Emergency Department: A Survey of Emergency Clinicians
Barkley, A., Lander, L. R., Dilcher, B., & Tuscano, M. (2024) · Western Journal of Emergency Medicine · doi:10.5811/westjem.18029 · Cited by 1
The impact of medication-assisted treatment for opioid use disorder on congestive heart failure outcomes
Rasmussen, P., Kuo, Y., Digbeu, B. D. E., Harmouch, W., Mai, S., & Raji, M. A. (2024) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2024.100456 · Cited by 1
Use and perceptions of involuntary civil commitment among post‐overdose outreach staff in Massachusetts, United States: A mixed‐methods study
Cummins, E., Walley, A. Y., Xuan, Z., Yan, S., Schoenberger, S. F., Formica, S. W., Bagley, S. M., Beletsky, L. A., Green, T. C., Lambert, A. M., et al. (2024) · Addiction · doi:10.1111/add.16690 · Cited by 1
Self-citation
Ethical Considerations in Civil Commitments for Substance Use Disorders
Nichols, C. (2024) · International Journal of Social Work Values and Ethics · doi:10.55521/10-021-210 · Cited by 1
Systems analysis and improvement to optimize opioid use disorder care quality and continuity for patients exiting jail (SAIA-MOUD)
Gimbel, S., Basu, A., Callen, E., Flaxman, A. D., Heidari, O., Hood, J. E., Kellogg, A., Kern, E., Tsui, J. I., Turley, E., et al. (2024) · Implementation Science · doi:10.1186/s13012-024-01409-0 · Cited by 1
Perspectives of substance use disorder counselors on the benefits and drawbacks of medications for opioid use disorder
Cardamone, N. C., Stewart, R. E., Kampman, K. M., & Marcus, S. C. (2025) · Addiction Science & Clinical Practice · doi:10.1186/s13722-025-00537-2 · Cited by 1
Methadone in the madness: a case series and review of methadone management in hospital settings
Mullins, C. F., Walsh, S., & Fitzgerald, J. (2025) · Pain Management · doi:10.1080/17581869.2025.2479411 · Cited by 1
Factors contributing to the expansion of medication for opioid use disorder (MOUD) within the New Hampshire Department of Corrections (NHDOC)
Clayman, N., Eamranond, P. P., Hanks, H., Mitcheff, M., RappaMannion, L., York, D., Mattis, P., Guinen, H., Carp, A., Olson, L., et al. (2025) · Health & Justice · doi:10.1186/s40352-025-00333-9 · Cited by 1
Multi-ancestry genome-wide association meta-analysis of buprenorphine treatment response
Davis, C. N., Khan, Y., Crist, R. C., Vickers‐Smith, R., Hartwell, E. E., Gelernter, J. E., Kampman, K. M., Kember, R. L., Moigne, A. L., Laffont, C. M., et al. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02117-z · Cited by 1
Description of Physician Champion Efforts to Expand Buprenorphine Treatment in Primary Care and Explore a Quality Implementation Measure of Success: Buprenorphine as a Percentage of All Opioids Prescribed
Salmon, T., South, A.-M., & Lofwall, M. R. (2025) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001535 · Cited by 1
Pilot testing a novel remotely delivered intensive outpatient program for hospitalized patients with opioid use disorder
Szpak, V., Velez, A., Prostko, S., Rosenblum, N., Maurer, R., Aguiar, L. J., Weiss, R. D., & Suzuki, J. (2025) · Addiction Science & Clinical Practice · doi:10.1186/s13722-025-00589-4 · Cited by 1
Problematic use of prescription opioid drugs: Classification and effective treatments
Ruiz, A. I. H. (2019) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2019.04.010 · Cited by 1
An untapped potential in addressing the opioid epidemic
Ventricelli, D. J., & Melton, S. T. (2019) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2019.07.019 · Cited by 1
Association between buprenorphine/naloxone and high-dose opioid analgesic prescribing in Kentucky, 2012–2017
Luu, H., Slavova, S. S., Freeman, P. R., Lofwall, M. R., Browning, S. R., Slade, E., & Bush, H. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.107606 · Cited by 2
Training Medical Students, Residents, and Fellows in Opioid Use Disorder Treatment
Morford, K. L., Falker, C. G., & Tetrault, J. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-80818-1_11 · Cited by 1
Association between clinically recognized suicidality and subsequent initiation or continuation of medications for opioid use disorder
Frost, M. C., Richards, J. A., Blosnich, J. R., Hawkins, E. J., Tsui, J. I., Edelman, E. J., & Williams, E. C. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109521 · Cited by 1
Addiction III: From mouse to man
Grigson, P. S., & Hobkirk, A. L. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.12.001 · Cited by 2
Emergency Medical Services Buprenorphine: Just Because They Can?
Delbridge, T. R., & Miller, S. N. (2021) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2021.03.022 · Cited by 1
Higher Buprenorphine Dose Associated with Increased Treatment Retention at Mobile Buprenorphine Clinic: A Retrospective Cohort StudyPreprint
Selitsky, L., Nordeck, C. D., Truong, A. Q., Agus, D., & Buresh, M. E. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4188937 · Cited by 1
Should emergency departments be prescribing buprenorphine/naloxone?
Bhat, C., Zworth, M., & Rosenberg, H. (2023) · Canadian Journal of Emergency Medicine · doi:10.1007/s43678-023-00594-z · Cited by 1
A Qualitative Analysis on the Views and Experiences of Involuntary Civil Commitment of People Who Use Drugs in Massachusetts (Section 35)Preprint
Silcox, J., Rapisarda, S. S., Hughto, J. M. W., Vento, S. A., Case, P., Palacios, W. R., Zaragoza, S., Shrestha, S., Stopka, T. J., & Green, T. C. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4662563 · Cited by 1
Self-citation
A two-dose regimen of Qβ virus-like particle-based vaccines elicit protective antibodies against heroin and fentanylPreprint
Romano, I. G., Johnson‐Weaver, B. T., Core, S. B., Jamus, A. N., Brackeen, M. F., Blough, B. E., Dey, S., Huang, Y., Staats, H. F., Wetsel, W. C., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.28.608988 · Cited by 1
Influence of Nurse’s Knowledge and Attitudes on Caring Behaviors for People with Opioid Use DisorderPreprint
Essien-Aleksi, I. E., Zhang, Y., Roosan, D., Mcpadden, T., Rideout, L., Martín, M. O., Beniers, P.-J., Lund, A., Leone-Sheehan, D. M., & Wurcel, A. G. (2025) · medRxiv · doi:10.1101/2025.05.22.25328156 · Cited by 1
The ELEVATE Maternal Health Center of Excellence: A Program to Reduce Maternal Morbidity From Substance Use Disorder in Utah
Johnson, E. P., Smid, M. C., Cohen, S. R., Watt, M. H., Debbink, M. P., Gordon, A. J., Smith, J. D., Turok, D. K., Charles, J. E., Parker, E., et al. (2025) · Substance Use & Addiction Journal · doi:10.1177/29767342251336860 · Cited by 1
Commentary on Rege et al. (2018): Naloxone reports to US poison centers highlight overdose prevention opportunities
Oliva, E. M., & Bounthavong, M. (2018) · Addiction · doi:10.1111/add.14443
Use of Buprenorphine to Treat Opioid Use Disorder
Bartholow, L. A. M., & Pope, J. (2018) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20181012-02
Quality & safety in the literature: May 2019
Houchens, N., Gupta, A. B., & Meddings, J. A. (2019) · BMJ Quality & Safety · doi:10.1136/bmjqs-2019-009401
Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Mortality
Brennan, L. V. (2019) · Annals of Internal Medicine · doi:10.7326/l18-0684
Adjunctive psychosocial interventions for opioid use disorder
WOODY, G. E. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30078-1
Epidemiology: Opioid Use and Related Disorders
Binswanger, I. A., Glanz, J. M., & Ford, M. A. (2019) · Current clinical psychiatry · doi:10.1007/978-3-030-16257-3_2
Target Population: Treatment-Resistant Opioid Use Disorder and the Role of Therapeutic Communities
Kast, K. A. (2019) · Springer eBooks · doi:10.1007/978-3-030-26273-0_6
An Introduction to the Opioid Epidemic and Therapeutic Communities
Kast, K. A., & Avery, J. (2019) · Springer eBooks · doi:10.1007/978-3-030-26273-0_1
Hospital Medicine Update: High-Impact Literature from March 2018 to April 2019
Donovan, A. K., Burger, A., Moriates, C. P., Sharpe, B. A., & Herzke, C. A. (2019) · Journal of Hospital Medicine · doi:10.12788/jhm.3321
Referrals to an Opioid Overdose Program with EMS Involvement: Comparing Treatment Outcomes
Haas, C. (2019) · IRL - University of Missouri, St. Louis (University of Missouri–St. Louis)
Buprenorphine implants: review of literature evidence and impacts on subjects with opioid use disorders
Riglietta, M. (2020) · Minerva Psichiatrica · doi:10.23736/s0391-1772.20.02070-1
Inpatient opioid use disorder treatment for the infectious disease physician
Seval, N., Eaton, E., & Springer, S. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-68328-9.00010-2
Outpatient opioid use disorder treatment for the ID physician
Muthulingam, D., Madden, L. M., & Altice, F. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-68328-9.00009-6
Substance use disorders
Ventricelli, D. J., & Peterson, A. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820007-0.00040-4 · Cited by 1
Patient Education on Medication Assisted Treatment for Opioid Use Disorder
Torres, N. J. (2020) · UA Campus Repository (The University of Arizona)
Buprenorphine Induction in Primary Care Using an In-Office Approach
Terry, T. D. (2021) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2021.01.023
CLINICAL AND SOCIAL ASPECTS OF HEROIN ADDICTION: MODERN STATE OF ISSUE
Gulyamov, S., Sharapova, N., & Krivoruchko, Y. D. (2020) · Avicenna Bulletin · doi:10.25005/2074-0581-2020-22-1-112-119
Reply to Letter to the Editor Regarding Article: “Considering the Potential Benefits of Over-The-Counter Naloxone” [Response To Letter]
Evoy, K. E., Hill, L. G., & Davis, C. S. (2021) · Integrated Pharmacy Research and Practice · doi:10.2147/iprp.s327403
Mischief, Mayhem, and Remediation.
Tamburello, A. C., & Haston, L. (2021) · PubMed · doi:10.29158/jaapl.210010-21

Authors: Larochelle, M. R., Bernson, D., Land, T., Stopka, T. J., Wang, N., Xuan, Z., Bagley, S. M., Liebschutz, J. M., & Walley, A. Y.
Affiliations: Boston University (US)
Massachusetts Department of Public Health (US)
Tufts University (US)
ORCID: Larochelle, Marc R.
Bernson, Dana
Stopka, Thomas J.
Wang, Na
Xuan, Ziming
Bagley, Sarah M.
Liebschutz, Jane M.
Walley, Alexander Y.
Venue: Annals of Internal Medicine
Publisher: American College of Physicians
Published: 2018-08-07
Volume: 169
Issue: 3
Pages: 137-145
ISSN: 0003-4819 (ISSN-L)
1539-3704
DOI: 10.7326/m17-3107
PMC: PMC6387681
OpenAlex: W2808907017
Cited by: 1,076
References: 38
Citations by year: 2026: 99 · 2025: 140 · 2024: 161 · 2023: 133 · 2022: 134 · 2021: 157 · 2020: 117 · 2019: 113 · 2018: 21
FWCI: 97.09
Type: journal article
Language: en
Open access: green
europepmc.org
Licence: www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
Locations: Annals of Internal Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (UL1TR001430)
National Institute on Drug Abuse (K23DA042168)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Health Sciences › Medicine › Epidemiology › HIV, Drug Use, Sexual Risk
Keywords: opioid use disorder, medication-assisted treatment, methadone maintenance treatment, buprenorphine, naltrexone, opioid-related deaths, all-cause mortality, opioid overdose prevention
MeSH terms: Adolescent, Adult, Analgesics, Opioid, Buprenorphine, Female, Humans, Male, Massachusetts, Methadone, Middle Aged, Mortality, Naltrexone, Opioid-Related Disorders, Retrospective Studies, Proportional Hazards Models, Young Adult, Opiate Substitution Treatment, Drug Overdose

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks